User:Wenchege/sandbox

Oslo Cancer Cluster is an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and treatment. It is a national non-profit member organization with about 90 members. The members are Norwegian and international companies, research and financial institutions, university hospitals and organizations – all working in the cancer field. They represent the entire oncology value chain, doing everything from exploratory research to selling therapeutics and diagnostics to global markets. The General Manager of Oslo Cancer Cluster is Ketil Widerberg and the Chairman of the Board is Øyvind Konstun Arnesen.

Norwegian Centre of Expertise:  Oslo Cancer Cluster was founded in 2006. In 2007, the cluster became a Norwegian Centre of Expertise (NCE). There are 12 NCEs. NCE is a governmental initiative for internationally oriented clusters with the highest potential for further growth. The NCE programme aims to strengthen innovation and internationalization processes in clusters based on collaboration between companies, research and development and educational institutions and public sector. The NCE programme is a joint venture between Innovation Norway, The Research Council of Norway and the Industrial Development Corporation of Norway (SIVA).

The Incubator Environment:  Around 30 of the members are gathered in the Oslo Cancer Cluster Incubator, a biotech cluster, situated in the Oslo Cancer Cluster Innovation Park. We share the innovation park with Ullern Upper Secondary School, the Cancer Registry of Norway and Oslo University Hospital. Next door is the leading comprehensive cancer hospital in Northern Europe, Oslo University Hospital Radiumhospitalet, and its Institute for Cancer Research. Oslo Cancer Cluster collaborates closely with them and has a long-term school-industry collaboration with Ullern Upper Secondary School since 2009.

Immuno-Oncology:  A growing number of members in the cluster develop novel cancer immunotherapies. Therefore, the cluster established the Norwegian Immuno-Oncology Consortium in 2013. The goal of the consortium is to strengthen the knowledge-base and expertise, and to facilitate more national and international collaboration within immuno-oncology. The consortium also addresses precision medicine.

Precision Medicine:  New technology, including tumour sequencing, is generating vast amounts of data that needs to be sorted and analysed. This has opened for IT-companies to take part in developing personalized medicine, tailoring drugs to the biology of each patient. Oslo Cancer Cluster is part of a EU Horizon 2020 project with innovative approaches to digitized healthcare and of collaborations with technological research facilities such as the Lawrence Livermore National Laboratory in the US and the Cancer Registry of Norway. Oslo Cancer Cluster initiated the Norwegian Cancer Genomic Consortium in 2012. It consists of clinicians and specialised cancer research groups collaborating on two large research projects that aim to establish new clinical practises for cancer treatment.